Physician profile
Gene Cheng
NPI 1679534770
$21,708.19
in general payments reported to CMS, 2019-2025
43 companies · $3,321 in 2025
The $3,321 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,417 · 2020: $2,341 · 2021: $2,818 · 2022: $3,069 · 2023: $3,828 · 2024: $3,915 · 2025: $3,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,954.40 |
| Education | $109.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,087.99 | 2019-2025 | Ubrelvy, Qulipta, Synthroid |
| Pfizer INC. | $2,876.74 | 2019-2025 | |
| Amgen INC. | $1,768.28 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,490.62 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,267.35 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,100.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $1,091.32 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $999.05 | 2019-2025 | Gardasil 9, Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $695.39 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $665.02 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $617.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $568.16 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Janssen Pharmaceuticals, INC | $550.89 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $540.59 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $426.63 | 2019-2025 | Veozah, Myrbetriq |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.